Utility of the Total Thrombus-formation Analysis System as a tool for evaluating thrombogenicity and monitoring antithrombotic therapy in pediatric Fontan patients

doi:10.21203/rs.3.rs-2071563/v1

Download PDF

Research Article

Utility of the Total Thrombus-formation Analysis System as a tool for evaluating thrombogenicity and monitoring antithrombotic therapy in pediatric Fontan patients

https://doi.org/10.21203/rs.3.rs-2071563/v1

This work is licensed under a CC BY 4.0 License

You are reading this latest preprint version

Background: Despite the major clinical complication of thromboembolic events after the Fontan procedure, there is no consensus regarding the optimal antithrombotic therapy. Novel tools to assess thrombogenicity are desirable to establish optimal thromboprophylaxis in this patient population. The Total Thrombus-formation Analysis System (T-TAS) was developed for the quantitative analysis of thrombus formation using microchips with thrombogenic surfaces. This study evaluated the utility of T-TAS in the assessment of thrombogenicity in pediatric Fontan patients.

Methods and results: The participants included 20 consecutive Fontan patients who underwent cardiac catheterization and 30 healthy controls. Blood samples collected without and with antithrombotic therapy (aspirin or aspirin and warfarin) were used for T-TAS to compute the area under the curve (AUC) in the atheroma (AR10-AUC30) and platelet (PL18-AUC10) chips. T-TAS values showed that patients in the Fontan group without antithrombotic therapy had lower thrombogenicity than those in the control group (PL18-AUC10, median [interquartile range] 356 [313–394] vs. 408 [392–424]; AR10-AUC30, median [interquartile range] 1270 [1178–1351] vs. 1382 [1338–1421]). Aspirin and warfarin therapies significantly decreased PL18-AUC10and AR10-AUC30, respectively, compared with those of patients without antithrombotic therapy (P<0.001 for each comparison). Subgroup analysis divided by low (<9 mmHg) or high (≥ 9 mmHg) central venous pressure (CVP) showed that CVP affects the reduction in AR10-AUC30with antithrombotic therapy.

Conclusions: T-TAS may be a useful tool for monitoring thrombogenicity and antithrombotic therapy in Fontan patients.

T-TAS

Fontan procedure

thrombogenicity

thromboembolism

aspirin

warfarin

The Fontan procedure is the final palliative operation commonly performed in children with single ventricle physiology. Thromboembolism is one of the most important complications in children after this procedure. The prevalence of thromboembolism after the Fontan surgery ranges from 17–33%, with a mortality rate of 25% [1, 2].

The current clinical guidelines suggest that thromboprophylaxis after the Fontan procedure is adequate to reduce the risk of thromboembolism. However, these guidelines emphasize a need for further studies to gather sufficient evidence to determine optimal antithrombotic therapy [3, 4]. In children, thromboprophylaxis after the Fontan procedure is typically performed with antiplatelet (aspirin) and anticoagulation (warfarin) therapies. A previous randomized controlled trial found no significant difference between these two drugs in the Fontan postoperative group [5]. The use of direct oral anticoagulant (DOAC) therapy after the Fontan procedure may be a promising alternative for thromboprophylaxis; however, there are insufficient data to recommend DOACs. Moreover, in Japan, bleeding-related complications are common with antithrombotic therapy, especially anticoagulation with warfarin [6].

The risk of thromboembolism after Fontan surgery increases over time and is expected to be lower in children than in adults. Abnormalities of various coagulation and fibrinolytic factors have been reported after Fontan surgery, making it difficult to assess the thrombogenicity in individual patients using conventional tests [7–10]. Hence, novel tools for monitoring the thrombogenicity and efficacy of antithrombotic therapy are needed to establish optimal antithrombotic therapy.

The Total Thrombus-formation Analysis System (T-TAS; Fujimori Kogyo Co Ltd., Japan) is an automated flow chamber system using microchips for simple analysis of the thrombus formation process in whole blood samples under blood flow mimicking in vivo conditions [11]. Several studies have shown that T-TAS is a useful diagnostic tool for monitoring therapy or predicting bleeding events [12–15].

Thus, we hypothesized that T-TAS would be a useful index for assessing thrombogenicity and the efficacy of antithrombotic therapy in patients after the Fontan procedure. This study investigated whether T-TAS is useful in assessing thrombogenicity and antithrombotic therapy in pediatric Fontan patients.

Study population and protocol

This observational study enrolled 21 consecutive Fontan patients who underwent cardiac catheterization at Kumamoto University Hospital from October 2020 to September 2021. All patients had received two-drug antithrombotic therapy with aspirin (4 mg/kg) and warfarin. Warfarin was controlled with a target prothrombin time international normalized ratio (PT-INR) of 1.5–2.0.

We excluded patients with postoperative periods of < 1 and > 10 years, a history of thrombosis or arrhythmias, and moderate or severe atrioventricular valve regurgitation. We excluded one patient with a postoperative period of > 10 years, and the remaining 20 patients were included in the present study (details of the Fontan group are shown in Table 1). Since there were no pediatric T-TAS reference values, we recruited a control group of 30 children with no organic abnormalities and no family history of thrombosis. The children in the control group had visited our hospital after an abnormal ECG or heart murmur was noted during school or medical examinations (Fig. 1a).

Table 1

Patient characteristics
Variable	n = 20
Age at Fontan operation, median (range), years	2.7 (1.9–4.1)
Postoperative time, median (range), years	4.9 (1.9–7.4)
Systemic ventricular type (RV/BV/LV)	(RV8/BV1/LV11)
Anatomic diagnosis, n (%)
TA	3 (15)
PA	5 (25)
HLHS	1 (5)
CAVC	2 (10)
Heterotaxy	3 (15)
other	6 (30)
Type of Fontan, n (%)	TCPC (EC) 20 (100)
Medication
ACE-I	15 (75)
Beta blocker	2 (10)
Diuretics	5 (25)
Antiarrthymic drug	0
Genetic syndromes
trisomy21	2 (10)
Major complication
PLE	1 (5)

Values are presented as mean ± SD or n (%), unless otherwise stated.

RV, right ventricle; BV, biventricular; LV, left ventricle; TA, tricuspid valve atresia; PA, pulmonary valve atresia; HLHS, hypoplastic left heart syndrome; CAVC, common atrioventricular canal; ACE-1, angiotensin converting enzyme inhibitor; PLE, protein-losing enteropathy.

All procedures were conducted in accordance with the Declaration of Helsinki and its amendments. The study protocol was approved by the human ethics committee of Kumamoto University, and written informed consent was obtained from each patient’s family.

Hemodynamics evaluation by cardiac catheterization

Intracardiac and great vessel pressures, including central venous pressure (CVP), were measured. Oxygen consumption was estimated using age, sex, and heart rate; cardiac index (CI; l/min/m²) was measured using Fick's principle. Systemic arterial resistance (Rs) and pulmonary arterial resistance (Rp) were also calculated.

Anticoagulation regimen and collection of blood samples

According to the regular clinical protocol, aspirin and warfarin were discontinued for 14 days prior to cardiac catheterization in the Fontan group. Aspirin was resumed the day after cardiac catheterization. Warfarin was resumed 3 weeks after cardiac catheterization. Blood samples were obtained at the time of catheterization (drug-free point), 3 weeks after the resumption of aspirin (on aspirin), and 1 month after the resumption of warfarin (on aspirin and warfarin) (Fig. 1b).

Blood samples were collected from the antecubital vein using a 21-gauge butterfly needle. Whole blood samples for the T-TAS assay were kept at room temperature for 1–4 hours before the T-TAS assay. The blood samples for the biomarker assay were prepared immediately after collection: plasma samples were centrifuged at 2,000 g for 10 minutes at 4°C and serum samples were centrifuged at 3,000 rpm for 5 minutes at room temperature.

Blood samples were anticoagulated as follows: benzylsulfonyl-D-argininyl-prolyl-4-amidinobenzylamide (BAPA) or 3.2% sodium citrate were used for T-TAS assays, ethylenediaminetetraacetic acid or 3.2% sodium citrate were used for complete blood cell counts (CBC), or coagulation assays and plasma brain natriuretic peptide assays. Further, we measured the following various biomarkers of coagulation and fibrinolysis: activated partial thromboplastin time (APTT), PT international normalized ratio (PT-INR), fibrinogen (FIB), antithrombin III (ATIII), von Willebrand factor (vWF), thrombomodulin (TM), thrombin- antithrombin complex (TAT), D-dimer, α2-plasmin inhibitor complex (PIC), protein C activity (protein C), and coagulation factors V (FV), VII (FVII), and VIII (FVIII). Serum samples were obtained from blood without anticoagulation, and were used for measuring the levels of albumin, bilirubin, aspartate aminotransferase, alanine aminotransferase, γ-glutamyl transpeptidase, urea nitrogen, and creatinine. In this study, all biomarkers were measured using commercially available kits.

Measurement of thrombogenicity using T-TAS

T-TAS is an automated microchip-based flow chamber system developed for easy and rapid assessment of platelet thrombus formation under flow conditions [11–14].

Briefly, using a simple procedure, this system analyzes different thrombus-forming processes using two disposable microchips with different thrombogenic surfaces.

A whole blood sample (330 µL) anticoagulated with BAPA was applied to one of the chips (a platelet chip [PL-chip] coated with type I collagen) at a flow rate of 18 µL min^− 1, corresponding to an initial wall shear rate of 1500 s^− 1. Inside the microchip, platelets adhere and aggregate on the surface of collagen, occluding the microchip capillaries. The other chip, the atheroma chip (AR-chip), is coated with type I collagen plus tissue thromboplastin. A whole blood sample collected into 3.2% sodium citrate was mixed with CaCl₂ and corn trypsin inhibitor immediately before the assay. The sample was then applied into the AR-chip at a flow rate of 10 µL min^− 1, corresponding to an initial wall shear rate of 600 s^− 1. Inside the microchip, activation of both the platelets and coagulation system is triggered simultaneously by collagen and tissue thromboplastin, respectively. The area under the flow pressure curve (AUC) was computed to assess platelet thrombogenicity inside the microchips. The PL₁₈-AUC₁₀ parameter represents the AUC for the first 10 minutes for the PL-chip, tested at a flow rate of 18 µL min^− 1. AR₁₀-AUC₃₀ represents the AUC for the first 30 minutes for the AR-chip, tested at a flow rate of 10 µL min^− 1.

Statistical analysis

No information was missing in the dataset of all participants who met the inclusion criteria and not the exclusion criteria. To describe the characteristics of the enrolled participants of the current study, data were summarized as median and interquartile range (IQR) for continuous variables and number and percentage for categorical variables. Correlation of parameters was evaluated using Spearman’s rank correlation coefficient. Next, to evaluate the treatment effect of aspirin and/or warfarin on parameters of blood coagulation, linear mixed effect models were applied using random effects by participant. In this model, the variance-covariance structure of the random effects was set as unstructured. In the subgroup analysis, interactions were evaluated using likelihood ratio tests. Fitting for each mixed model was visually examined using a standardized normal probability plot. All statistical analyses were performed using Stata 15.0 (StataCorp, College Station, TX, USA). All P-values were two-tailed, and P < 0.05 was considered statistically significant.

T-TAS parameters and baseline characteristics

The baseline characteristics of the control and Fontan groups are shown in Table 2.

Table 2

Baseline characteristics of the Fontan and control groups
	Control group (n = 30)	Fontan group (n = 20)	P value
Age, median (y)	7.0	7.9	0.80
(IQR)	(5.5, 9.3)	(6.5, 8.7)
Male (%)	55.0	53.3	0.57
WBC (x10³/µL)	6.95	6.80	0.14
(IQR)	(5.80, 8.00)	(4.55, 7.25)
Hb (g/dL)	13.1	14.1	0.019
(IQR)	(12.9, 13.6)	(13.2, 14.5)
Ht (%)	38.9	42.1	0.007
(IQR)	(37.7, 40.0)	(38.8, 43.8)
PLT (×10³)	301	243	0.023
(IQR)	(258, 333)	(208, 295)
APTT (sec)	31.4	32.3	0.12
(IQR)	(29.4, 32.9)	(30.4, 34.2)
PT-INR	1.02	1.18	< 0.001
(IQR)	(0.97, 1.04)	(1.12, 1.25)
FIB (mg/dL)	259	262	0.45
(IQR)	(221, 292)	(237.5, 298.5)

The values presented are median (interquartile range: 25th–75th percentile).

Bold values indicate statistical significance.

Hb, hemoglobin; Hct, hematocrit; WBC, white blood cell; PLT, platelet count; APTT, activated partial thromboplastin time; PT-INR, PT international normalized ratio; FIB, fibrinogen.

Age and sex were not significantly different between the two groups. There were significant differences in hemoglobin, hematocrit, platelet count, and PT-INR between the two groups. The Fontan group had higher levels of hemoglobin, hematocrit, and PT-INR and lower platelet counts than the control group.

Table 3 and Fig. 2 show that PL₁₈-AUC₁₀ and AR₁₀-AUC₃₀ were significantly lower in the Fontan group than in the control group (PL₁₈-AUC₁₀ median [IQR] 356 [313–394] vs. 408 [392–424], p < 0.001; AR₁₀-AUC₃₀ median [IQR] 1270 [1178–1351] vs. 1382 [1338–1421], p < 0.001).

Table 3

T-TAS parameters in the Fontan and control groups
	Control group (n = 30)	Fontan group (n = 20)	P value
PL₁₈-AUC₁₀	408	356	< 0.001
IQR	(392, 424)	(313, 394)
AR₁₀-AUC₃₀	1382	1270	< 0.001
IQR	(1338, 1421)	(1178, 1351)

The values presented are median (interquartile range: 25th–75th percentile).

Bold values indicate statistical significance.

PL₁₈-AUC₁₀, area under the curve for the first 10 minutes for the platelet chip tested at a flow rate of 18 µL/min; AR₁₀-AUC₃₀, area under the curve for the first 30 minutes for the atheroma chip tested at a flow rate of 10 µL/min.

Table 4

Correlation of T-TAS measurements with blood components and hemodynamics.
	PL₁₈-AUC₁₀		AR₁₀-AUC₃₀
Variables	Rho	P value	Rho	P value
Blood Tests
WBC(×10³/µL)	0.282	0.23	0.179	0.45
Hb (g/dL)	0.247	0.29	0.146	0.54
Ht (%)	0.336	0.15	0.194	0.41
PLT (×10³)	0.528	0.017	0.623	0.003
Albumin (g/dL)	0.183	0.44	0.347	0.13
T-bil (mg/dL)	-0.074	0.76	-0.16	0.50
AST (U/L)	-0.007	0.98	0.042	0.86
ALT (U/L)	0.033	0.89	0.080	0.74
γGTP (U/L)	0.141	0.55	0.044	0.86
BUN (mg/dL)	-0.249	0.29	-0.317	0.17
Crea (mg/dL)	-0.227	0.34	-0.336	0.15
BNP (pg/mL)	-0.266	0.26	-0.078	0.75
APTT (sec)	-0.242	0.30	-0.002	0.99
PT-INR	0.020	0.93	-0.108	0.65
FIB (mg/dL)	-0.038	0.88	0.114	0.63
ATⅢ (%)	0.030	0.90	0.214	0.36
Protein C activity (%)	0.264	0.26	0.221	0.35
D-cimmer (µg/mL)	-0.113	0.63	-0.294	0.21
TAT (ng/mL)	-0.327	0.16	-0.131	0.58
PIC (µg/mL)	-0.299	0.20	-0.088	0.71
FV (%)	-0.334	0.16	-0.067	0.79
FⅦ (%)	-0.350	0.15	-0.283	0.26
FⅧ (%)	0.380	0.11	0.289	0.23
vWF (Ag) (%)	0.108	0.65	-0.031	0.90
TM (U/ml)	-0.345	0.14	-0.094	0.69
Hemodynamics
CI (l/min/m2)	-0.406	0.076	-0.421	0.06
CVP (mmHg)	-0.495	0.026	-0.194	0.41
Rs (Wood units)	0.622	0.003	0.429	0.06
Rp (Wood units)	0.047	0.84	0.296	0.21
SaO₂ (%)	0.325	0.16	-0.086	0.72

Bold values indicate statistical significance.

T-bil, total- bilirubin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γGTP, γ-glutamyl transpeptidase; BUN, urea nitrogen; Crea, creatinine; BNP, brain natriuretic peptide; APTT, activated partial thromboplastin time; PT-INR, PT international normalized ratio; FIB, fibrinogen; ATⅢ, antithrombin III; TAT, thrombin- antithrombin complex; PIC, α2- plasmin inhibitor complex; F, factor; vWF, von Willebrand factor; TM, thrombomodulin; CI, cardiac index: CVP, central venous pressure; Rs, systemic artery resistance: Rp, pulmonary artery resistance; SaO₂, arterial oxygen saturation.

Laboratory data and hemodynamic parameters affecting T-TAS parameters in Fontan patients

Further, we analyzed factors affecting the T-TAS parameters in Fontan patients not treated with antithrombotic therapy. The platelet count was significantly correlated with PL₁₈-AUC₁₀ and AR₁₀-AUC₃₀. Other CBC and biomarkers tested were irrelevant. Regarding hemodynamic parameters, PL₁₈-AUC₁₀ was negatively correlated with CVP and positively correlated with Rs (Table. 4).

Effects of aspirin and warfarin on T-TAS parameters, APTT, and PT-INR

To evaluate the utility of PL₁₈-AUC₁₀ and AR₁₀-AUC₃₀ measured by T-TAS,

we compared the parameters with and without antithrombotic therapy in Fontan patients. Serial changes in T-TAS parameters (PL₁₈-AUC₁₀ and AR₁₀-AUC₃₀) and APTT and PT-INR with no antithrombotic therapy, aspirin therapy, and aspirin and warfarin combination therapy are shown in Fig. 3a–d.

As widely known, APTT and PT-INR were not significantly different with aspirin therapy compared with no antithrombotic therapy but were significantly increased with warfarin therapy (APTT, 35.4 [95%confidence interval (95%CI) 33.9–36.8] vs 32.4 [95%CI 31.4–33.4]; PT-INR, 1.85 [95%CI 1.67–2.02] vs 1.20 [95%CI1.16–1.24]; P < 0.001). Contrarily, PL₁₈-AUC₁₀ were significantly lower with aspirin therapy than with no antithrombotic therapy (169 [95%CI 125–214] vs 352 [95%CI 327–376]; P < 0.001). AR₁₀-AUC₃₀ showed a decreasing trend with aspirin therapy, although not significantly different, and was significantly lower with add-on warfarin therapy than without antithrombotic therapy (1167 [95%CI 1110–1225] vs 1252 [95%CI 1196–1307]; P < 0.001).

CVP impacts the reduction of AR₁₀-AUC₃₀ with antithrombotic therapy

Subsequently, we next examined the association between T-TAS parameters and CVP and CI, considering the possibility that the effects of elevated CVP and decreased cardiac output, which are characteristics of the Fontan circulation, on the coagulation system are associated with a risk of hemorrhagic complications due to antithrombotic therapy. Negative correlations were found between the reduction in AR₁₀-AUC₃₀ and CVP (rho − 0.7686, P < 0.001). Therefore, we focused on AR₁₀-AUC₃₀ over time in the high/low CVP groups (2 levels: divided by median [CVP 9 mmHg]) at each time point (3 levels: drug-free, aspirin, aspirin and warfarin).

During aspirin therapy, AR₁₀-AUC₃₀ was significantly decreased in the high CVP group compared with that in the low CVP group (high CVP group, 1172 [95%CI 1091–1253]; low CVP group, 1264 [95%CI 1224–1304]). AR₁₀-AUC₃₀ was still lower in the high CVP group compared with that in the low CVP group after additional therapy with warfarin (high CVP group, 1122 [95%CI 1034–1210]; low CVP group, 1223 [95%CI117–1269]) (Fig. 3f). However, there were no significant differences in the reduction in PL₁₈-AUC₁₀ (Fig. 3e), APTT (Fig. 3g), and PT-INR (Fig. 3h).

The main feature of the present study was the assessment of whole blood thrombogenicity using T-TAS in pediatric Fontan patients. The main findings were as follows: (1) pediatric Fontan patients had less propensity for thrombogenicity than controls, as assessed by T-TAS; (2) PL₁₈-AUC₁₀ and AR₁₀-AUC₃₀ could be useful markers for monitoring the antithrombotic effects of aspirin and warfarin; and (3) the degree of reduction in AR₁₀-AUC₃₀ with antithrombotic therapy may reflect the hemodynamics of Fontan patients, i.e., the impact of elevated CVP on the coagulation system. To the best of our knowledge, this is the first report to describe the utility of T-TAS as a tool for evaluating thrombogenicity and monitoring antithrombotic therapy in Fontan patients.

The Fontan circulation presents a thrombotic environment and associated complex pathophysiology affecting all three elements of Virchow’s triad: endothelial cell dysfunction, abnormal blood flow, and increased coagulability [6, 7]

Several studies have reported hypercoagulability caused by coagulation factor abnormalities and platelet activation after Fontan surgery. The risk of thromboembolism is also expected to increase as endothelial and multiorgan damage associated with congestion progresses over time [1, 16, 17]. Few pediatric cohort studies have investigated thromboembolic phenomena in Fontan circulation, and our knowledge of coagulopathy in pediatric Fontan patients is limited.

The main advantage of the T-TAS system is that it assesses thrombus formation under flow conditions using whole blood samples. Thus, to some extent, T-TAS reflects physiological conditions [11, 18]. Some studies have also demonstrated the usefulness of T-TAS in detecting abnormal coagulation and platelet function [13, 19–21]. Therefore, we believe that T-TAS is suitable for evaluating thrombogenicity in Fontan patients with abnormal blood flow, various coagulation factor abnormalities, and platelet activation.

The present study found that pediatric Fontan patients showed a low propensity for thrombus formation. This result is supported by reports of a decreased risk of thromboembolism within 1 year and after 10 years of Fontan surgery, as well as reports of more bleeding events with antithrombotic therapy in children [1, 6].

Using thromboelastography, Leslie et al. also did not find hypercoagulability in pediatric Fontan patients [22]. T-TAS can quantitatively measure the thrombogenic process under physiological flow conditions and is sensitive enough to detect abnormalities in platelet and coagulation function. This suggests that T-TAS may be more suitable for assessing thrombogenic potential in specific Fontan circulation.

In this study, we examined factors affecting T-TAS parameters in pediatric Fontan patients and found a positive correlation between platelet counts and T-TAS parameters. In previous reports, the platelet count was significantly related to the AUC of T-TAS in healthy participants [23, 24] Since Fontan patients tend to have low platelet counts due to factors such as splenomegaly caused by elevated portal pressure, careful attention should be paid to the evaluation of T-TAS when platelet counts are extremely low.

Reportedly, in a good Fontan circulation, CVP decreases and Rs increases during childhood, and perfusion pressure is maintained [25]. In the current study, increasing PL₁₈-AUC₁₀ was positively correlated with lower CVP and increased Rs, suggesting that adequate primary hemostatic performance may be maintained in these patients with preserved good perfusion pressure of the Fontan circulation.

This study shows that the antiplatelet effects of aspirin and anticoagulant effects of warfarin can be monitored by T-TAS, as reported in adult patients with cardiovascular diseases.These results suggest that T-TAS can be used to evaluate aspirin resistance, which is often a problem in thromboprophylaxis in postoperative Fontan patients [26, 27]. Moreover, T-TAS is reportedly a useful monitoring tool for DOACs [14, 15]. DOACs for thromboprophylaxis in Fontan patients have recently been considered [28]. We believe that T-TAS could be useful for monitoring this patient population.

In addition, we found a significant association between a reduction in AR₁₀-AUC₃₀ and CVP due to anticoagulation therapy. The Fontan circulation results in a low flow rate condition due to elevated venous pressure driving pulmonary arterial blood flow. A reduced flow rate propagates the initiation of the coagulation system and increases the likelihood of thrombus formation. Hepatic dysfunction and protein-losing enteropathy due to elevated CVP may further compound the coagulation abnormalities and provide an additional mechanism for the dysregulation of hemostasis [29–31]. AR₁₀-AUC₃₀ can evaluate the reduction in thrombogenicity by anticoagulation reflecting Fontan hemodynamics, which is not observed by PT-INR or APTT. This suggests that assessment by T-TAS may be suitable for risk stratification of bleeding complications associated with thromboprophylaxis, which may reflect the hemodynamic impact on the coagulation system in Fontan patients.

This study had some limitations. First, this single-center observational study had a small sample size which could lead to an overestimation of the results. Second, the clinical outcomes (thrombotic and bleeding events) associated with antithrombotic therapy have not been assessed. Finally, as previously reported, there are individual differences in T-TAS parameters [23]. To better assess thrombogenicity by T-TAS, multiple evaluations in the same individual are desirable. Further large population studies are needed to examine the relationship between T-TAS parameters and clinical outcomes in Fontan patients and to establish optimal antithrombotic therapy.

In conclusion, the present study demonstrated that T-TAS may be a useful tool for monitoring thrombogenicity in Fontan patients. AR₁₀-AUC₃₀ and PL₁₈-AUC₁₀ measured by T-TAS are potentially suitable indices for the assessment of antithrombotic therapy in Fontan patients.

Funding:This study was supported in part by the research grant of The Morinaga Hoshikai (Tokyo, Japan), which had no role in the study design, data collection, data analyses, and interpretation of the study data, nor were involved in the decision to publish the final manuscript.

Ethics approval: All procedures were conducted in accordance with the Declaration of Helsinki and its amendments. The study protocol was approved by the human ethics committee of Kumamoto University.

Conflicts of interest: All authors declare that they have no conflict of interest.

Informed Consent: Informed consent was obtained from all individual participants included in the study.

Author Contributions:

Osamu Matsuo: Conceptualization, Methodology, Investigation, Data curation, Writing - original draft.

Masanobu Ishii: Conceptualization, Methodology, Investigation, Writing - original draft.

Kaikita Koichi: Conceptualization, Methodology, Supervision.

Fumiya Miyamura: Investigation.

Jun Morinaga: Formal analysis, Data curation.

Shiro Matsumoto: Investigation, Validation.

Kenichi Tsujita:Writing - Review & Editing, Supervision.

Kimitoshi Nakamura: Project administration, Supervision.

All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation

S. Van Den Helm, C.N. Sparks, V. Ignjatovic, P. Monagle, C. Attard (2022) Increased risk for thromboembolism after Fontan surgery: considerations for thromboprophylaxis. Front. Pediatr 10 803408. https://doi.org/10.3389/fped.2022.803408.
M. Firdouse, A. Agarwal, A.K. Chan, T. Mondal (2014) Thrombosis and thromboembolic complications in Fontan patients: a literature review. Clin. Appl. Thromb. Hemost 20: 484–492. https://doi.org/10.1177/1076029613520464.
P. Monagle, A.K.C. Chan, N.A. Goldenberg, R.N. Ichord, J.M. Journeycake, U. Nowak-Göttl, S.K. Vesely (2012) Antithrombotic Therapy in Neonates and Children: Antithrombotic Therapy and Prevention of Thrombosis, ninth ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141, pp. e737S–e801S. https://doi.org/10.1378/chest.11-2308
K.K. Stout, C.J. Daniels, J.A. Aboulhosn, B. Bozkurt, C.S. Broberg, J.M. Colman, S.R. Crumb et al (2019) 2018 AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 139 e698–e800. https://doi.org/10.1161/CIR.0000000000000603.
P. Monagle, A. Cochrane, R. Roberts, C. Manlhiot, R. Weintraub, B. Szechtman, M. Hughes, M. Andrew, B.W. Mccrindle (2011) Fontan Anticoagulation Study Group, A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children. J. Am. Coll. Cardiol 58: 645–651. https://doi.org/10.1016/j.jacc.2011.01.061.
H. Ohuchi, K. Yasuda, A. Miyazaki, S. Ono, Y. Hayama, J. Negishi, K. Noritake et al (2015) Prevalence and predictors of haemostatic complications in 412 Fontan patients: their relation to anticoagulation and haemodynamics. Eur. J. Cardiothorac Surg 47: 511–519. https://doi.org/10.1093/ejcts/ezu145.
M. Jahangiri, J. Kreutzer, D. Zurakowski, E. Bacha, R.A. Jonas (2000) Evaluation of hemostatic and coagulation factor abnormalities in patients undergoing the Fontan operation. J. Thorac. Cardiovasc. Surg 120: 778–782. https://doi.org/10.1067/mtc.2000.108903.
V. Chaloupecký, I. Svobodová, I. Hadaćová, V. Tomek, B. Hučín, T. Tláskal, J. Janoušek et al (2005) Coagulation profile and liver function in 102 patients after total cavopulmonary connection at mid term follow up. Heart 91: 73–79. https://doi.org/10.1136/hrt.2003.026419.
K.C. Odegard, F.X. McGowan, D. Zurakowski, J.A. DiNardo, R.A. Castro, P.J. del Nido, P.C. Laussen (2002) Coagulation factor abnormalities in patients with single-ventricle physiology immediately prior to the Fontan procedure. Ann. Thorac. Surg 73: 1770–1777. https://doi.org/10.1016/S0003-4975(02)03580-4.
L. Idorn, A.S. Jensen, K. Juul, J.I. Reimers, P.I. Johansson, K.E. Sørensen, S.R. Ostrowski et al (2013) Thromboembolic complications in Fontan patients: population-based prevalence and exploration of the etiology. Pediatr. Cardiol 34: 262–272. https://doi.org/10.1007/s00246-012-0431-4.
K. Hosokawa, T. Ohnishi, T. Kondo, M. Fukasawa, T. Koide, I. Maruyama, K.A. Tanaka (2011) A novel automated microchip flow-chamber system to quantitatively evaluate thrombus formation and antithrombotic agents under blood flow conditions. J. Thromb. Haemost 9: 2029–2037. https://doi.org/10.1111/j.1538-7836.2011.04464.x.
K. Kaikita, K. Hosokawa, J.R. Dahlen, K. Tsujita (2019) Total Thrombus-Formation Analysis System (T-TAS): clinical application of quantitative analysis of thrombus formation in cardiovascular disease. Thromb. Haemost 119: 1554–1562. https://doi.org/10.1055/s-0039-1693411.
J. Sikora, A. Karczmarska-Wódzka, J. Bugieda, P. Sobczak (2021) The Use of Total Thrombus Formation Analysis System as a Tool to Assess Platelet Function in Bleeding and Thrombosis risk-A systematic review. Int. J. Mol. Sci 22: 8605. https://doi.org/10.3390/ijms22168605.
M. Ito, K. Kaikita, D. Sueta, M. Ishii, Y. Oimatsu, Y. Arima, S. Iwashita et al (2016) Total Thrombus-Formation Analysis System (T-TAS) can predict periprocedural bleeding events in patients undergoing catheter ablation for atrial fibrillation. J. Am. Heart Assoc 5: e002744. https://doi.org/10.1161/JAHA.115.002744.
M. Ishii, K. Kaikita, M. Ito, D. Sueta, Y. Arima, S. Takashio, Y. Izumiya et al (2017) Direct oral anticoagulants form thrombus different from warfarin in a microchip flow chamber system. Sci. Rep 7: 7399. https://doi.org/10.1038/s41598-017-07939-6.
H. Kajimoto, M. Nakazawa, K. Murasaki, N. Hagiwara, T. Nakanishi (2009) Increased P-selectin expression on platelets and decreased plasma thrombomodulin in Fontan patients. Circ. J 73: 1705–1710. https://doi.org/10.1253/circj.CJ-08-1087.
L. Tomkiewicz-Pajak, P. Hoffman, O. Trojnarska, M. Lipczyńska, P. Podolec, A. Undas (2014) Abnormalities in blood coagulation, fibrinolysis, and platelet activation in adult patients after the Fontan procedure. J. Thorac. Cardiovasc. Surg 147: 1284–1290. https://doi.org/10.1016/j.jtcvs.2013.06.011.
K. Hosokawa, T. Ohnishi, H. Sameshima, N. Miura, T. Ito, T. Koide, I. Maruyama (2013) Analysing responses to aspirin and clopidogrel by measuring platelet thrombus formation under arterial flow conditions. Thromb. Haemost 109: 102–111. https://doi.org/10.1160/TH12-06-0441.
Y. Nakajima, K. Nogami, K. Yada, T. Kawamura, K. Ogiwara, S. Furukawa, N. Shimonishi et al (2020) Evaluation of clinical severity in patients with type 2N von Willebrand disease using microchip-based flow-chamber system. Int. J. Hematol 111: 369–377. https://doi.org/10.1007/s12185-019-02782-z.
Y. Nakajima, K. Yada, K. Ogiwara, S. Furukawa, N. Shimonishi, M. Shima, K. Nogami (2021) A microchip flow-chamber assay screens congenital primary hemostasis disorders. Pediatr. Int 63: 160–167. https://doi.org/10.1111/ped.14378.
S. Takashio, K. Kaikita, M. Nishi, M. Morioka, T. Higo, A. Shiose, T. Doman et al (2020) Detection of acquired von Willebrand syndrome after ventricular assist device by total thrombus-formation analysis system. ESC Heart Fail 7: 3235–3239. https://doi.org/10.1002/ehf2.12824.
L. Raffini, A. Schwed, X.L. Zheng, M. Tanzer, S. Nicolson, J.W. Gaynor, D. Jobes (2009) Thromboelastography of patients after Fontan compared with healthy children. Pediatr. Cardiol 30: 771–776. https://doi.org/10.1007/s00246-009-9434-1.
Y. Oda, T. Ito, Y. Yamada, T. Koga, T. Nagasato, T. Ohnishi-Wada, K. Hosokawa et al (2021) Cardiovascular risk factors are associated with augmented thrombogenicity in healthy individuals: analysis using the Total Thrombus-formation Analysis System. Thromb. J 19: 88. https://doi.org/10.1186/s12959-021-00341-3.
Y. Yamaguchi, T. Moriki, A. Igari, Y. Matsubara, T. Ohnishi, K. Hosokawa, M. Murata (2013) Studies of a microchip flow-chamber system to characterize whole blood thrombogenicity in healthy individuals. Thromb. Res 132: 263–270. https://doi.org/10.1016/j.thromres.2013.05.026.
H. Ohuchi, S. Ono, Y. Tanabe, K. Fujimoto, H. Yagi, H. Sakaguchi, A. Miyazaki, O. Yamada (2012) Long-term serial aerobic exercise capacity and hemodynamic properties in clinically and hemodynamically good, “excellent”, Fontan survivors.Circ. J 76: 195–203. https://doi.org/10.1253/circj.CJ-11-0540.
L. Tomkiewicz-Pajak, T. Wojcik, S. Chłopicki, M. Olszowska, J. Pajak, J. Podolec, B. Sitek et al (2015) Aspirin resistance in adult patients after Fontan surgery. Int. J. Cardiol 181: 19–26. https://doi.org/10.1016/j.ijcard.2014.11.219.
J. Patregnani, D. Klugman, D. Zurakowski, P. Sinha, R. Freishtat, J. Berger, Y. Diab (2016) High on aspirin platelet reactivity in pediatric patients undergoing the Fontan procedure. Circulation 134: 1303–1305. https://doi.org/10.1161/CIRCULATIONAHA.116.023457.
L.M. Pina, X. Dong, L. Zhang, M.N. Samtani, A.D. Michelson, H. Justino, D. Bonnet et al (2019) Rivaroxaban, a direct Factor Xa inhibitor, versus acetylsalicylic acid as thromboprophylaxis in children post-Fontan procedure: rationale and design of a prospective, randomized trial (the UNIVERSE study). Am. Heart J 213: 97–104. https://doi.org/10.1016/j.ahj.2019.04.009.
J. Rychik, K.M. Dodds, D. Goldberg, A.C. Glatz, M. Fogel, J. Rossano, J. Chen et al (2020) Protein losing enteropathy after Fontan operation: glimpses of clarity through the lifting fog. World J. Pediatr. Congenit. Heart Surg 11: 92–96. https://doi.org/10.1177/2150135119890555.
P.D. Coon, J. Rychik, R.T. Novello, P.S. Ro, J.W. Gaynor, T.L. Spray (2001) Thrombus formation after the Fontan operation. Ann. Thorac. Surg 71: 1990–1994. https://doi.org/10.1016/S0003-4975(01)02472-9.
J. Emamaullee, A.N. Zaidi, T. Schiano, J. Kahn, P.L. Valentino, R.E. Hofer, T. Taner et al (2020) Fontan-associated liver disease: screening, management, and transplant considerations. Circulation 142: 591–604. https://doi.org/10.1161/CIRCULATIONAHA.120.045597.

No competing interests reported.

Download PDF

Editorial decision: Major revision
04 Dec, 2022
Reviews received at journal
04 Dec, 2022
Reviewers agreed at journal
04 Dec, 2022
Reviewers invited by journal
18 Sep, 2022
Editor assigned by journal
17 Sep, 2022
Submission checks completed at journal
17 Sep, 2022
First submitted to journal
16 Sep, 2022

You are reading this latest preprint version

Utility of the Total Thrombus-formation Analysis System as a tool for evaluating thrombogenicity and monitoring antithrombotic therapy in pediatric Fontan patients

Status:

Version 1

Abstract

Figures

Introduction

Methods

Study population and protocol

Hemodynamics evaluation by cardiac catheterization

Anticoagulation regimen and collection of blood samples

Measurement of thrombogenicity using T-TAS

Statistical analysis

Results

T-TAS parameters and baseline characteristics

Laboratory data and hemodynamic parameters affecting T-TAS parameters in Fontan patients

Effects of aspirin and warfarin on T-TAS parameters, APTT, and PT-INR

CVP impacts the reduction of AR₁₀-AUC₃₀ with antithrombotic therapy

Discussion

Declarations

References

Additional Declarations

Status:

Version 1

Utility of the Total Thrombus-formation Analysis System as a tool for evaluating thrombogenicity and monitoring antithrombotic therapy in pediatric Fontan patients

Status:

Version 1

Abstract

Figures

Introduction

Methods

Study population and protocol

Hemodynamics evaluation by cardiac catheterization

Anticoagulation regimen and collection of blood samples

Measurement of thrombogenicity using T-TAS

Statistical analysis

Results

T-TAS parameters and baseline characteristics

Laboratory data and hemodynamic parameters affecting T-TAS parameters in Fontan patients

Effects of aspirin and warfarin on T-TAS parameters, APTT, and PT-INR

CVP impacts the reduction of AR10-AUC30 with antithrombotic therapy

Discussion

Declarations

References

Additional Declarations

Status:

Version 1

CVP impacts the reduction of AR₁₀-AUC₃₀ with antithrombotic therapy